DDInter927 DDInter1214
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors . It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents.
Midostaurin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Midostaurin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Midostaurin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Saxagliptin
Midostaurin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Midostaurin {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Midostaurin {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Midostaurin may lead to a major life threatening interaction when taken with Leflunomide
Midostaurin may lead to a major life threatening interaction when taken with Crizotinib